Guizhou Yibai Pharmaceutical Co., Ltd., a well-known brand of cough medicine, is a high-tech enterprise integrating research/development/production and sales of new drugs
Guizhou Yibai Pharmaceutical Co., Ltd. is a high-tech enterprise integrating research, development, production and sales of new drugs. The company was founded on June 12, 1995, completed the shareholding system reform in November 2000, and was successfully listed on the Shanghai Stock Exchange in March 2004 (stock code 600594), becoming the first non-public enterprise in Guizhou Province to obtain listing qualifications.
The company covers an area of 134398 square meters, and has a production plant of 43,200 square meters in line with the national drug production quality management practice (GMP). At present, it has 3 production bases in the province and 4 production bases outside the province. At present, there are 49 quality products such as small injections, lyophilized powder injections, large infusions, etc., and 9 injection production lines. It is equipped with cutting-edge production equipment of international advanced level.
As of December 2012, the company's industrial output value is nearly 3 billion yuan, sales revenue is nearly 2.8 billion yuan (group consolidated data), 386 million yuan in Guizhou Province in 2012, and the company has paid more than 2.3 billion yuan in taxes to the state since its establishment. From January to June 2013, the company's industrial output value has reached 1.16 billion yuan, the tax payment is 182 million yuan, and the sales revenue growth rate is stable at about 15% compared with last year.
In the process of development, the company has been committed to improving corporate governance and continuously improving the level of corporate governance. The company has formulated a standardized "Articles of Association" and the "Three Sessions" rules of procedure, implemented the independent director system, set up a strategic development committee, an audit committee, a nomination committee and a remuneration and assessment committee, formulated a strict and standardized financial system and information disclosure system, and formed a set of management mechanisms with clear rights and responsibilities and checks and balances, which provides an institutional guarantee for the sustainable and healthy development of the company.
The company has more than 4,000 employees, of which 81% have college degree or above. In line with the concept of "100 years of cultivating people", the company has always attached great importance to employee training, and has taken various forms of training for employees, and effectively improved the enthusiasm of all employees through learning and training, so that the overall quality of employees has been comprehensively improved. The company's senior management personnel are sent to Tsinghua University, China Europe International Business School, Stanford, Yangtze River School of Management, Shanghai Jiao Tong University and other national key universities for management learning, and the general manager training course is held within the company, well-known experts are hired to attend classes, and the company's management personnel and some outstanding employees are selected to participate, aiming to improve the comprehensive quality of management personnel. The company also sends professional and technical personnel to relevant pharmaceutical colleges for professional training, focusing on improving the company's technical strength and cultivating the spirit of innovation; Adhere to the worker training system, and constantly strengthen the improvement of workers' cultural quality, accomplishment and technical skills, and the company's employees will be trained accordingly in strict accordance with more than 300 hours of study per year. These measures provide a strong guarantee for the company to be equipped with a good management team, technical team and other reserve talents, and also lay a solid foundation for the sustainable development of the company.
At present, the company's main products are cough family series, Eddy injection, ginkgo darmol injection, loplatin for injection, compound cantharid capsules, qi-regulating and invigorating blood drop pills, prostate occlusion granules and many other advantageous varieties. Among these series of products that have formed enterprise advantages, compound Chinese medicine injection Aidi injection and compound cantharid capsule are new biphasic anti-tumor drugs, among which the research of Aidi injection has reached the gene level; The fourth-generation ginkgo preparation---- Ginkgo Damol Injection, is an effective treatment drug for heart, cerebrovascular and peripheral circulation disorders, and its advent has brought good news to the majority of patients with cardiovascular and cerebrovascular diseases; Loboplatina for injection is a national first-class new drug, the third generation of platinum antitumor drugs, compared with other platinum drugs, its toxicity is lower and drug resistance is smaller. The Qi and Blood Drop Pill is an exclusive original seedling drug, which is a first-line drug for the treatment of cardiovascular diseases and has great market potential.
In 2006, the company was approved as the thirteenth batch of "National Recognized Enterprise Technology Center", in 2006 it was approved as a postdoctoral workstation, in 2007 it was approved as "Guizhou Province New Drug Release System Drug Engineering Technology Research Center", in 2008 it was rated as a national innovative pilot enterprise, in 2008 it was built as a new drug research and development pilot base of Yibai Pharmaceutical, and in 2009 it was rated as a national and local joint engineering research center. In 2009, the National Development and Reform Commission awarded the "Southwest National Medicine New Preparation Engineering Research Center", in 2012, the National Development and Reform Commission awarded the "Southwest Region (Guizhou) Drug Production Mobilization Center", and in 2012, the Ministry of Science and Technology awarded the "National Innovative Enterprise".
Based on the comprehensive strength of the enterprise, Yibai Pharmaceutical has been ranked among the top 100 pharmaceutical companies in China for seven consecutive years and the top 20 most competitive pharmaceutical listed companies in China in 2012.
The company has always attached great importance to the protection of intellectual property rights, and in 2004 it set up a special intellectual property department, and took measures such as applying for patent protection and creating well-known trademarks, focusing on the development of core technologies and enhancing the ability of independent innovation of enterprises. As of the end of 2012, the company's patent applications and trademark applications ranked first in the same industry in the province, and ranked in the leading position in the same industry in China. Among them, the company has applied for 199 invention patents and authorized 115; 82 design patents have been applied for, and 76 have been authorized. 94 preclinical studies and registration applications have been completed, 7 clinical studies have been implemented, and a total of 27 production approvals have been obtained.
At present, the company has taken the lead in the establishment of Miao Medicine Group, and at the same time, it also plans to recruit the first batch of graduate students in Miao Medicine with Beijing University of Chinese Medicine. While strengthening the enterprise itself, it will create conditions for the development of Miao medicine and contribute to the development of Guizhou pharmaceutical industry.
The company has established a good marketing network in major cities across the country, equipped with a well-trained sales team, and realizes the quality tracking service of the whole process from products to patient services.
In order to promote the optimization of the structure of the pharmaceutical industry and improve the concentration of products, in line with the development concept of accelerating mergers and acquisitions and independent innovation, the company has successively acquired Guilin Lijiang Pharmaceutical, Yunnan Nanzhao Pharmaceutical, Guizhou National Pharmaceutical, Hainan Chang'an Pharmaceutical and other production-oriented pharmaceutical enterprises in the past few years. In 2012, Yibai once again accelerated the pace of its integration and mergers and acquisitions, acquired 80% of the shares of Beijing Amity Pharmaceutical Co., Ltd., and integrated the development, production and sales of genetic engineering drugs into Yibai's pharmaceutical and health industry chain.
As a leading enterprise in the pharmaceutical industry in Guizhou Province, relying on the "Guizhou Province Top Ten Industrial Industry Revitalization Plan" proposed by Guizhou Province and the "5 1" industrial system proposed by our city, the implementation of the "100 billion industry and 10 billion enterprises" plan, in order to promote the social and economic development of our province, invest 2 billion to build Yibai Industrial Park, the project officially started in early 2012. Yibai Industrial Park is located at the junction of Jinyang New District and Yunyan District, Guiyang City, covering an area of more than 600 acres, with a total construction area of 423648 square meters and a total investment of 1,940,364,900 yuan. The civil work of the preparation workshop has been completed, and now it has entered the stage of process equipment commissioning; The equipment enters the stage of trial operation and commissioning; It will be submitted to the State Food and Drug Administration before June 30, 2013 to apply for the new GMP certification. Once it passes the verification, it can ensure the simultaneous development of enterprise transformation and upgrading and drug market norms.
Yibai has always been committed to public welfare, in the early 2008 freezing disaster, Yibai immediately sent condolences to the people in the disaster area, and donated 600,000 yuan to support the disaster area; In the Wenchuan earthquake disaster in Sichuan Province in May 2008, we took the lead and donated a total of 1.24 million yuan in cash and 1 million yuan worth of medicines to the compatriots in the disaster area. In the drought disaster in Guizhou in early 2010, donated 2.8 million yuan in cash; And in a number of national poverty-stricken counties donated to support education. Ms. Dou Qiling, chairman and president of the company, established Hope Primary School in Hezhang County, a national-level poverty-stricken county. As of 2012, Yibai has donated more than 10 million yuan to the society.
With the mission of "excellent pharmaceutical product provider and excellent health care service leader", the company adheres to the values of "Health 100, Quality 100, Gratitude 100, Innovation 100" in the tide of the economic market, provides customers with high-quality, efficient products that meet environmental protection requirements, creates the greatest wealth for investors and creates the greatest value for the society. We will continue to move forward towards the vision of "becoming a respected company in China's pharmaceutical industry with sustainable business potential".
